Evidence Table C2. CONTINUOUS outcomes for class ANTI-BACTERIAL (TOPICAL)

Trial # Method	Compa-rison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	C.01.01			**Clindamycin**		**Vehicle**		
217 ↑ N=42 Parallel Mod		**Closed comedones (count)** Baseline counts: 44 (Target) / 39 (Comparator)	Mid (12)	Percent Change*: -25	*NS*	Percent Change*: -31	*NS*	**NS**
		Open comedones (count) Baseline counts: 30 (Target) / 13 (Comparator)	Mid (12)	Percent Change*: -34	*.01*	Percent Change*: 64	*NS*	**NS**
		Papules (count) Baseline counts: 33 (Target) / 40 (Comparator)	Mid (12)	Percent Change*: -36	*.01*	Percent Change*: -38	*.02*	**NS**
		Pustules (count) Baseline counts: 9 (Target) / 8 (Comparator)	Mid (12)	Percent Change*: -22	*NS*	Percent Change*: -13	*NS*	**NS**
		Severity (leeds)	Mid (12)	Measure: 1	*.01*	Measure: 1	*NS*	**NS**
		Severity/flash photo (leeds)	Mid (12)	Measure: 2	*.03*	Measure: 1	*.04*	**NS**
		Severity/fluorescent photo-face+nose (leeds)	Mid (12)	Measure: 1	*NS*	Measure: 1	*.001*	**0.02**
		Severity/fluorescent photo-nose (leeds)	Mid (12)	Measure: 1	*.001*	Measure: 2	*NS*	**NS**
		Severity/fluorescent photography	Mid (12)	Measure: 1	*.002*	Measure: 2	*NS*	**NS**
	C.01.01			**Clindamycin phosphate (lotion)**		**Placebo**		
99 ↓ N=135 Parallel Mod		**Papules (count)** Baseline counts: 21 (Target) / 23 (Comparator)	Short (6)	Percent Change*: -29		Percent Change*: -20		**0.05**
		Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -46		Percent Change*: -35		**NS**
		Papules (count) Baseline counts: 21 (Target) / 23 (Comparator)	Mid (12)	Percent Change*: -45		Percent Change*: -24		**0.05**
		Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Mid (12)	Percent Change*: -62		Percent Change*: -31		**0.05**
	C.01.01			**Clindamycin + vehicle**		**Vehicle (oral) + vehicle (topical)**		
33 N=87 Parallel Mild		**Inflammatory (count)** Baseline counts: 9 (Target) / 7 (Comparator)	Short (6)	Percent Change*: -68	*.0001*	Percent Change*: -12		**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method		Compa-rison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
33 Parallel	N=87 Mild		**Inflammatory (count)** Between P-value: compared to tetra.Baseline counts: 9 (Target) / 7 (Comparator)	Mid (8)	Percent Change*: -72	*.0001*	Percent Change*: -12	*NS*	**0.0004**
		C.01.01			**Clindamycin hydrochloride**		**Vehicle**		
20 Parallel	N=358 Mod		**Papules (count)** Baseline counts: 25 (Target) / 26 (Comparator)	Short (6)	Percent Change*: -64		Percent Change*: -166		**0.15**
			Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -61		Percent Change*: -32		**0.018**
327 Parallel	N=18 Mild/mod		**Nodules (count)** Baseline counts: 2 (Target) / 0 (Comparator)	Mid (8)	Percent Change*: -50	*NS*	Percent Change*: 500	*NS*	**NS**
			Papules (count) Baseline counts: 32 (Target) / 31 (Comparator)	Mid (8)	Percent Change*: -43	*NS*	Percent Change*: -23	*NS*	**NS**
20 Parallel	N=358 Mod		**Papules change (count)** Baseline counts: 25 (Target) / 26 (Comparator)	Mid (8)	Percent change*: -66		Percent change*: -42		**0.0022**
327 Parallel	N=18 Mild/mod		**Pustules (count)** Baseline counts: 2 (Target) / 1 (Comparator)	Mid (8)	Percent Change*: -56	*NS*	Percent Change*: -86	*NS*	**NS**
20 Parallel	N=358 Mod		**Pustules change (count)** Baseline counts: 4 (Target) / 4 (Comparator)	Mid (8)	Percent change*: -62		Percent change*: -43		**0.029**
		C.01.01			**Clindamycin phosphate**		**Vehicle**		
199 ↑ Parallel	N=45 Mild/mod		**Closed comedones (count)** Baseline counts: 6 (Target) / 8 (Comparator)	Short (3)	Percent Change*: 00	*NS*	Percent Change*: -17	*NS*	**NS***
			Nodes+cysts (count) Baseline counts: 1 (Target) / 1 (Comparator)	Short (3)	Percent Change*: -17	*sig*	Percent Change*: -50	*sig*	**NS**
			Open comedones (count) Baseline counts: 9 (Target) / 6 (Comparator)	Short (3)	Percent Change*: -09	*sig*	Percent Change*: 03	*NS*	**NS***
			Papules (count) Between P-value: no P value given.Baseline counts: 21 (Target) / 20 (Comparator)	Short (6)	Percent Change*: -39	*sig*	Percent Change*: -37	*sig*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
20 Parallel	N=358 Mod	**Papules (count)** Baseline counts: 26 (Target) / 26 (Comparator)	Short (6)	Percent Change*: -56		Percent Change*: -166		**0.15**
		Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -68		Percent Change*: -32		**0.018**
199 ↑ Parallel	N=45 Mild/mod	**Pustules (count)** Baseline counts: 5 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -31	*sig*	Percent Change*: -32	*sig*	**NS**
20 Parallel	N=358 Mod	**Papules change (count)** Baseline counts: 26 (Target) / 26 (Comparator)	Mid (8)	Percent change*: -56		Percent change*: -42		**0.0022**
		Pustules change (count) Baseline counts: 4 (Target) / 4 (Comparator)	Mid (8)	Percent change*: -72		Percent change*: -43		**0.029**
199 ↑ Parallel	N=45 Mild/mod	**Closed comedones (count)** Baseline counts: 6 (Target) / 8 (Comparator)	Mid (12)	Percent Change*: -39	*NS*	Percent Change*: -34	*NS*	**NS**
		Nodes+cysts (count) Baseline counts: 1 (Target) / 1 (Comparator)	Mid (12)	Percent Change*: -67	*sig*	Percent Change*: -25	*sig*	**NS**
		Open comedones (count) Baseline counts: 9 (Target) / 6 (Comparator)	Mid (12)	Percent Change*: -63	*sig*	Percent Change*: -17	*sig*	**NS**
		Papules (count) Baseline counts: 21 (Target) / 20 (Comparator)	Mid (12)	Percent Change*: -68	*sig*	Percent Change*: -51	*sig*	**NS**
		Pustules (count) Baseline counts: 5 (Target) / 4 (Comparator)	Mid (12)	Percent Change*: -71	*sig*	Percent Change*: -16	*sig*	**0.021**
	C.01.01			**Clindamycin phosphate (gel)**		**Placebo**		
99 ↓ Parallel	N=135 Mod	**Papules (count)** Baseline counts: 22 (Target) / 23 (Comparator)	Short (6)	Percent Change*: -36		Percent Change*: -20		**0.05**
		Pustules (count) Baseline counts: 5 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -39		Percent Change*: -35		**NS**
		Papules (count) Baseline counts: 22 (Target) / 23 (Comparator)	Mid (12)	Percent Change*: -49		Percent Change*: -24		**0.05**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
99 ↓ N=135 Parallel Mod		**Pustules (count)** Baseline counts: 5 (Target) / 4 (Comparator)	Mid (12)	Percent Change*: -59		Percent Change*: -31		**0.05**
	C.01.02			**Clindamycin**		**Nicotinamide**		
305 ↓ N=76 Parallel Mod		**Inflammatory change (%)**	Short (4)	Percent change: -44 (32.)		Percent change: -30 (37.)		**NS**
		Severity change (allen-smith %)	Short (4)	Measure: -27 (37.)		Measure: -18 (24.)		**NS**
		Inflammatory change (%)	Mid (8)	Percent change: -43 (41.)		Percent change: -60 (41.)		**NS**
		Severity (allen-smith)	Mid (8)	Measure: 3 (0.33)		Measure: 2 (0.39)		**NS**
		Severity change (allen-smith %)	Mid (8)	Measure: -38 (32.)		Measure: -52 (32.)		**NS**
	C.01.03			**Clindamycin phosphate (lotion)**		**Clindamycin phosphate (gel)**		
99 ↓ N=135 Parallel Mod		**Papules (count)** Baseline counts: 21 (Target) / 22 (Comparator)	Short (6)	Percent Change*: -29		Percent Change*: -36		**0.05**
		Pustules (count) Baseline counts: 4 (Target) / 5 (Comparator)	Short (6)	Percent Change*: -46		Percent Change*: -39		**NS**
		Papules (count) Baseline counts: 21 (Target) / 22 (Comparator)	Mid (12)	Percent Change*: -45		Percent Change*: -49		**0.05**
		Pustules (count) Baseline counts: 4 (Target) / 5 (Comparator)	Mid (12)	Percent Change*: -62		Percent Change*: -59		**0.05**
	C.01.03			**Clindamycin (gel)**		**Clindamycin (solution)**		
267 ↓ N=60 Parallel Mild		**Open comedones (count)** Baseline counts: 8 (Target) / 7 (Comparator)	Short (6)	Percent Change*: -37	*sig*	Percent Change*: -39	*sig*	**NS***
		Pustules (count) Baseline counts: 5 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -53	*sig*	Percent Change*: -48	*sig*	**NS***
		Open comedones (count) Baseline counts: 8 (Target) / 7 (Comparator)	Mid (12)	Percent Change*: -68	*sig*	Percent Change*: -61	*sig*	**NS***
		Pustules (count) Baseline counts: 5 (Target) / 4 (Comparator)	Mid (12)	Percent Change*: -75	*sig*	Percent Change*: -75	*sig*	**NS***
	C.01.03			**Clindamycin (lotion)**		**Clindamycin (solution)**		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
131 ↑ N=70 Parallel Mod/sev		**Closed comedones (count)** Baseline counts: 57 (Target) / 39 (Comparator)	Short (6)	Percent Change*: -19		Percent Change*: 04		
		Open comedones (count) 6 Baseline counts: 10 (Target) / 5 (Comparator)	Short (6)	Percent Change*: -22		Percent Change*: 14		
		Papules (count) Baseline counts: 45 (Target) / 42 (Comparator)	Short (6)	Percent Change*: -12		Percent Change*: 07		
		Pustules (count) Baseline counts: 16 (Target) / 25 (Comparator)	Short (6)	Percent Change*: 04		Percent Change*: 04		
		Severity (goltz)	Short (6)	Measure: 2 (0.5)		Measure: 2 (0.6)		**NS***
		Closed comedones (count) Baseline counts: 57 (Target) / 39 (Comparator)	Mid (12)	Percent Change*: -50		Percent Change*: -22		
		Open comedones (count) Baseline counts: 10 (Target) / 5 (Comparator)	Mid (12)	Percent Change*: -61		Percent Change*: -46		
		Papules (count) Baseline counts: 45 (Target) / 42 (Comparator)	Mid (12)	Percent Change*: -30		Percent Change*: -28		
		Pustules (count) Baseline counts: 16 (Target) / 25 (Comparator)	Mid (12)	Percent Change*: -27		Percent Change*: -24		
		Severity (goltz)	Mid (12)	Measure: 2 (0.5)	*.01*	Measure: 2 (0.6)	*.01*	**NS***
	C.01.03			**Clindamycin (solution)**		**Clindamycin (gel)**		
267 ↓ N=60 Parallel Mild		**Open comedones (count)** Baseline counts: 7 (Target) / 8 (Comparator)	Short (6)	Percent Change*: -39	*sig*	Percent Change*: -37	*sig*	**NS***
		Pustules (count) Baseline counts: 4 (Target) / 5 (Comparator)	Short (6)	Percent Change*: -48	*sig*	Percent Change*: -53	*sig*	**NS***
		Open comedones (count) Baseline counts: 7 (Target) / 8 (Comparator)	Mid (12)	Percent Change*: -61	*sig*	Percent Change*: -68	*sig*	**NS***
		Pustules (count) Baseline counts: 4 (Target) / 5 (Comparator)	Mid (12)	Percent Change*: -75	*sig*	Percent Change*: -75	*sig*	**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
	C.01.03			**Clindamycin (solution)**		**Clindamycin (lotion)**		
131 ↑ N=70 Parallel Mod/sev		**Closed comedones (count)** Baseline counts: 39 (Target) / 57 (Comparator)	Short (6)	Percent Change*: 04		Percent Change*: -19		
		Open comedones (count) Baseline counts: 5 (Target) / 10 (Comparator)	Short (6)	Percent Change*: 14		Percent Change*: -22		
		Papules (count) Baseline counts: 42 (Target) / 45 (Comparator)	Short (6)	Percent Change*: 07		Percent Change*: -12		
		Pustules (count) Baseline counts: 25 (Target) / 16 (Comparator)	Short (6)	Percent Change*: 04		Percent Change*: 04		
		Severity (goltz)	Short (6)	Measure: 2 (0.6)		Measure: 2 (0.5)		**NS***
		Closed comedones (count) Baseline counts: 39 (Target) / 57 (Comparator)	Mid (12)	Percent Change*: -22		Percent Change*: -50		
		Open comedones (count) Baseline counts: 5 (Target) / 10 (Comparator)	Mid (12)	Percent Change*: -46		Percent Change*: -61		
		Papules (count) Baseline counts: 42 (Target) / 45 (Comparator)	Mid (12)	Percent Change*: -28		Percent Change*: -30		
		Pustules (count) Baseline counts: 25 (Target) / 16 (Comparator)	Mid (12)	Percent Change*: -24		Percent Change*: -27		
		Severity (goltz)	Mid (12)	Measure: 2 (0.6)	*.01*	Measure: 2 (0.5)	*.01*	**NS***
	C.01.03			**Clindamycin hydrochloride**		**Clindamycin phosphate**		
20 N=358 Parallel Mod		**Papules (count)** Baseline counts: 25 (Target) / 26 (Comparator)	Short (6)	Percent Change*: -64		Percent Change*: -56		**0.15**
		Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -61		Percent Change*: -68		**0.018**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method		Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
20 Parallel	N=358 Mod		**Papules change (count)** Baseline counts: 25 (Target) / 26 (Comparator)	Mid (8)	Percent change*: -66		Percent change*: -56		**0.0022**
			Pustules change (count) Baseline counts: 4 (Target) / 4 (Comparator)	Mid (8)	Percent change*: -62		Percent change*: -72		**0.029**
143 ↑ Parallel	N=42 split face Sev		**Nodules (count)** Baseline counts: 11 (Target) / 9 (Comparator)	Mid (12)	Percent Change*: -100		Percent Change*: -78		
			Papules (count) Baseline counts: 14 (Target) / 14 (Comparator)	Mid (12)	Percent Change*: 221		Percent Change*: 214		
			Pustules (count) Baseline counts: 214 (Target) / 192 (Comparator)	Mid (12)	Percent Change*: -87		Percent Change*: -88		
		C.01.03			**Clindamycin phosphate**		**Clindamycin hydrochloride**		
20 Parallel	N=358 Mod		**Papules (count)** Baseline counts: 26 (Target) / 25 (Comparator)	Short (6)	Percent Change*: -56		Percent Change*: -64		**0.15**
			Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -68		Percent Change*: -61		**0.018**
			Papules change (count) Baseline counts: 26 (Target) / 25 (Comparator)	Mid (8)	Percent change*: -56		Percent change*: -66		**0.0022**
			Pustules change (count) Baseline counts: 4 (Target) / 4 (Comparator)	Mid (8)	Percent change*: -72		Percent change*: -62		**0.029**
143 ↑ Parallel	N=42 split face Sev		**Nodules (count)** Baseline counts: 9 (Target) / 11 (Comparator)	Mid (12)	Percent Change*: -78		Percent Change*: -100		
			Papules (count) Baseline counts: 14 (Target) / 14 (Comparator)	Mid (12)	Percent Change*: 214		Percent Change*: 221		**NS**
			Pustules (count) Baseline counts: 192 (Target) / 214 (Comparator)	Mid (12)	Percent Change*: -88		Percent Change*: -87		
		C.01.03			**Clindamycin phosphate (gel)**		**Clindamycin phosphate (lotion)**		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
99 ↓ Parallel	N=135 Mod	**Papules (count)** Baseline counts: 22 (Target) / 21 (Comparator)	Short (6)	Percent Change*: -36		Percent Change*: -29		**0.05**
		Pustules (count) Baseline counts: 5 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -39		Percent Change*: -46		**NS**
		Papules (count) Baseline counts: 22 (Target) / 21 (Comparator)	Mid (12)	Percent Change*: -49		Percent Change*: -45		**0.05**
		Pustules (count) Baseline counts: 5 (Target) / 4 (Comparator)	Mid (12)	Percent Change*: -59		Percent Change*: -62		**0.05**
	C.01.04			**Clindamycin**		**Erythromycin**		
326 Parallel	N=72 Mod/sev	**Closed comedones (count)** Count location: Both sides. Baseline counts: 28 (Target) / 22 (Comparator)	Short (4)	Percent Change*: -24		Percent Change*: -18		**NS***
		Closed comedones (count)	Short (4)	Percent Change*: -24		Percent Change*: -18		**NS***
303 Parallel	N=178 Mod	**Inflammatory (count)** Count location: Entire face. Baseline counts: 20 (Target) / 22 (Comparator)	Short (4)	Percent Change*: -40		Percent Change*: -35		**Duncan**
326 Parallel	N=72 Mod/sev	**Non-inflammatory (count)** Count location: Both sides. Baseline counts: 47 (Target) / 58 (Comparator)	Short (4)	Percent Change*: -24		Percent Change*: -38	*NS*	**NS***
303 Parallel	N=178 Mod	**Non-inflammatory (count)** Count location: Entire face. Baseline counts: 56 (Target) / 53 (Comparator)	Short (4)	Percent Change*: -37		Percent Change*: -27		**Duncan**
326 Parallel	N=72 Mod/sev	**Non-inflammatory (count)** Count location: Both sides. Baseline counts: 47 (Target) / 58 (Comparator)	Short (4)	Percent Change*: -24		Percent Change*: -38	*NS*	**NS***
244 ↑ Parallel	N=120 Mild/mod	**Papules change (%)**	Short (4)	Percent change: -28		Percent change: -33		
		Pustules change (%)	Short (4)	Percent change: -37		Percent change: -61		
326 Parallel	N=72 Mod/sev	**Total inflammatory (count)** Count location: Both sides. Baseline counts: 23 (Target) / 22 (Comparator)	Short (4)	Percent Change*: -31		Percent Change*: -22		**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
326 Parallel	N=72 Mod/sev	**Total inflammatory (count)** Count location: Both sides. Baseline counts: 23 (Target) / 22 (Comparator)	Short (4)	Percent Change*: -31		Percent Change*: -22		**NS***
244 ↑ Parallel	N=120 Mild/mod	**Comedones change (%)**	Mid (8)	Percent change: -10		Percent change: -15		
		Dryness change (score)	Mid (8)	Measure: 0		Measure: 0		
		Dryness change (score)	Mid (8)	Measure: 0		Measure: 0		
		Erythema change (score)	Mid (8)	Measure: 0		Measure: 0		
		Inflammatory change (%)	Mid (8)	Percent change: -37		Percent change: -49		
		Total lesions change (%)	Mid (8)	Percent change: -27		Percent change: -31		
326 Parallel	N=72 Mod/sev	**Closed comedones (count)** Count location: Both sides. Baseline counts: 28 (Target) / 22 (Comparator)	Mid (12)	Percent Change*: -26	*.0006*	Percent Change*: 00	*NS*	**0.0213**
		Closed comedones (count)	Mid (12)	Percent Change*: -26	*.0006*	Percent Change*: 00	*NS*	**0.0213**
303 Parallel	N=178 Mod	**Inflammatory (count)** Count location: Entire face. Baseline counts: 20 (Target) / 22 (Comparator)	Mid (12)	Percent Change*: -59	*.001*	Percent Change*: -62	*.001*	**Duncan**
326 Parallel	N=72 Mod/sev	**Nodes+cysts (count)** Count location: Both sides. Baseline counts: 2 (Target) / 2 (Comparator)	Mid (12)	Percent Change*: -41	*NS*	Percent Change*: -40	*NS*	**NS**
		Nodes+cysts (count)	Mid (12)	Percent Change*: -41	*NS*	Percent Change*: -40	*NS*	**NS**
		Non-inflammatory (count) Count location: Both sides. Baseline counts: 47 (Target) / 58 (Comparator)	Mid (12)	Percent Change*: 00	*.03*	Percent Change*: 00	*NS*	**NS**
303 Parallel	N=178 Mod	**Non-inflammatory (count)** Count location: Entire face. Baseline counts: 56 (Target) / 53 (Comparator)	Mid (12)	Percent Change*: -39	*.001*	Percent Change*: -43	*.001*	**Duncan**
326 Parallel	N=72 Mod/sev	**Non-inflammatory (count)** Count location: Both sides. Baseline counts: 47 (Target) / 58 (Comparator)	Mid (12)	Percent Change*: 00	*.03*	Percent Change*: 00	*NS*	**NS**
		Open comedones (count) Count location: Both sides. Baseline counts: 20 (Target) / 37 (Comparator)	Mid (12)	Percent Change*: -55	*NS*	Percent Change*: -52	*NS*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
326 N=72 Parallel Mod/sev		**Open comedones (count)** Count location: Both sides. Baseline counts: 20 (Target) / 37 (Comparator)	Mid (12)	Percent Change*: -55	*NS*	Percent Change*: -52	*NS*	**NS**
		Total inflammatory (count) Count location: Both sides. Baseline counts: 23 (Target) / 22 (Comparator)	Mid (12)	Percent Change*: -01	*.0001*	Percent Change*: 00	*.0001*	**NS**
		Total inflammatory (count)	Mid (12)	Percent Change*: -01	*.0001*	Percent Change*: 00	*.0001*	**NS**
		Total lesions (count) Count location: Both sides.	Mid (12)	Raw count: 37	*.003*	Raw count: 45	*.01*	**NS**
		Total lesions (count)	Mid (12)	Raw count: 37	*.003*	Raw count: 45	*.01*	**NS**
	C.01.04			**Clindamycin phosphate**		**Erythromycin**		
158 ↑ N=120 Parallel Mod		**Comedones (count)** Baseline counts: 34 (Target) / 29 (Comparator)	Short (4)	Percent Change*: -05		Percent Change*: -11		
		Cysts change (%)	Short (4)	Percent change: 0		Percent change: 0		
		Inflammatory (count)	Short (4)	Raw count: 18		Raw count: 15		
		Total lesions change (%)	Short (4)	Percent change: 50		Percent change: 41		
		Comedones change (%) Count location: Face.	Mid (8)	Percent change: 15		Percent change: -15		**NS**
		Cysts change (%)	Mid (8)	Percent change: 0		Percent change: 0		
		Inflammatory change (%) Count location: Face.	Mid (8)	Percent change: -9		Percent change: -39		**0.003**
		Overall change/investigator	Mid (8)	Measure: 56		Measure: 80		**0.012**
		Total lesions change (%) Count location: Face.	Mid (8)	Percent change: -9		Percent change: -29		
		Total lesions change (count) Baseline counts: 57 (Target) / 53 (Comparator)	Mid (8)	Percent change*: 85		Percent change*: 75		**0.0183**
	C.01.05			**Clindamycin**		**Tetracycline**		
291 ↑ N=92 Parallel Mild		**Open comedones change (count)** Baseline counts: 7 (Target) / 7 (Comparator)	Short (6)	Percent change*: -30		Percent change*: 70		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
291 ↑ N=92 Parallel Mild		**Papules change (count)** Baseline counts: 13 (Target) / 13 (Comparator)	Short (6)	Percent change*: -61		Percent change*: -60		**NS**
		Pustules change (count) Baseline counts: 6 (Target) / 6 (Comparator)	Short (6)	Percent change*: -64		Percent change*: -56		**NS**
		Open comedones change (count) Baseline counts: 7 (Target) / 7 (Comparator)	Mid (8)	Percent change*: -28		Percent change*: 57		**NS**
		Papules change (count) Baseline counts: 13 (Target) / 13 (Comparator)	Mid (8)	Percent change*: -71		Percent change*: -63		**NS**
		Pustules change (count)	Mid (8)	Measure: -4		Measure: -4		**NS**
	C.01.05			**Clindamycin**		**Tetracycline hydrochloride**		
261 ↓ N=52 Parallel Mild/mod		**Total lesions (count)** Count location: Both sides.	Short (6)	Raw count: 7		Raw count: 13		
		Total lesions (count)	Mid (8)	Raw count: 6		Raw count: 14		
	C.01.06			**Clindamycin**		**Benzoyl Peroxide**		
329 N=79 Parallel Mod		**Comedones (count)** Count location: Unspecified. Baseline counts: 61 (Target) / 43 (Comparator)	Short (6)	Percent Change*: -02		Percent Change*: -19		
		Cysts (count) Count location: Unspecified.	Short (6)	Raw count: 1		Raw count: 3		
		Irritancy (score) Between P-value: C < B.	Short (6)	Measure: 0		Measure: 1		**NS**
		Papules (count) Count location: Unspecified. Baseline counts: 21 (Target) / 16 (Comparator)	Short (6)	Percent Change*: -38		Percent Change*: -19		
		Pustules (count) Count location: Unspecified. Baseline counts: 8 (Target) / 8 (Comparator)	Short (6)	Percent Change*: -25		Percent Change*: -63		
		Severity change (michaelsson %) Count location: Unspecified.	Short (6)	Measure: -36		Measure: -42		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
329 N=79 Parallel Mod		**Comedones (count)** Count location: Unspecified. Baseline counts: 61 (Target) / 43 (Comparator)	Mid (10)	Percent Change*: -15		Percent Change*: -19		
		Cysts (count) Count location: Unspecified.	Mid (10)	Raw count: 0		Raw count: 1		
		Irritancy (score) Between P-value: C < B.	Mid (10)	Measure: 0		Measure: 1		**NS**
		Papules (count) Count location: Unspecified. Baseline counts: 21 (Target) / 16 (Comparator)	Mid (10)	Percent Change*: -45		Percent Change*: -59		
		Pustules (count) Count location: Unspecified. Baseline counts: 8 (Target) / 8 (Comparator)	Mid (10)	Percent Change*: -44		Percent Change*: -72		
		Severity change (michaelsson %) Count location: Unspecified.	Mid (10)	Measure: -47		Measure: -59		**0.05**
	C.01.06			**Clindamycin phosphate**		**Benzoyl peroxide**		
324 ↑ N=60 Parallel Mod		**Local reactions/Oiliness**	Short (1.	Measure: 1 (1.2)		Measure: 1 (1.2)		**0.05**
		Inflammatory change (%)	Short (4)	Percent change: -26 (6.6)	*.01*	Percent change: -28 (6.4)	*.01*	**NS**
		Local reactions/Dryness	Short (4)	Measure: 1 (2.7)		Measure: 1 (2.7)		**0.05**
		Local reactions/Erythema	Short (4)	Measure: 1		Measure: 1		**NS**
		Local reactions/Oiliness	Short (4)	Measure: 1 (2.7)		Measure: 1 (2.7)		**0.05**
		Local reactions/Peeling	Short (4)	Measure: 0 (3.1)		Measure: 1 (3.1)		**0.05**
		Non-inflammatory change (%)	Short (4)	Percent change: -29 (12.)	*.002*	Percent change: -32 (18.)	*.001*	**NS**
		Total lesions change (%)	Short (4)	Percent change: -27 (16.)	*.001*	Percent change: -31 (23.)	*.001*	**NS**
		Inflammatory change (%)	Mid (12)	Percent change: -28 (7.6)	*.006*	Percent change: -52 (11.)	*.02*	**NS**
		Local reactions/Dryness	Mid (12)	Measure: 1 (1.2)		Measure: 2 (1.2)		**NS**
		Local reactions/Erythema	Mid (12)	Measure: 1		Measure: 1		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
324 ↑ N=60 Parallel Mod		**Local reactions/Peeling**	Mid (12)	Measure: 1 (2.4)		Measure: 1 (2.4)		**0.05**
		Non-inflammatory change (%)	Mid (12)	Percent change: -37 (16.)	*.002*	Percent change: -63 (35.)	*.001*	**0.001**
		Total lesions change (%)	Mid (12)	Percent change: -34 (21.)	*.001*	Percent change: -60 (44.)	*.001*	**NS**
	C.02.03			**Clindamycin + Benzoyl Peroxide**		**Benzoyl Peroxide**		
329 N=79 Parallel Mod		**Comedones (count)** Count location: Unspecified. Baseline counts: 47 (Target) / 43 (Comparator)	Short (6)	Percent Change*: -32		Percent Change*: -19		
		Cysts (count) Count location: Unspecified.	Short (6)	Raw count: 1		Raw count: 3		
		Irritancy (score) Between P-value: C + B < B.	Short (6)	Measure: 0		Measure: 1		**NS**
		Papules (count) Count location: Unspecified. Baseline counts: 19 (Target) / 16 (Comparator)	Short (6)	Percent Change*: -32		Percent Change*: -19		
		Pustules (count) Count location: Unspecified. Baseline counts: 10 (Target) / 8 (Comparator)	Short (6)	Percent Change*: -60		Percent Change*: -63		
		Severity change (Michaelsson %) Count location: Unspecified.	Short (6)	Measure: -50		Measure: -42		
		Comedones (count) Count location: Unspecified. Baseline counts: 47 (Target) / 43 (Comparator)	Mid (10)	Percent Change*: -47		Percent Change*: -19		
		Cysts (count) Count location: Unspecified.	Mid (10)	Raw count: 1		Raw count: 1		
		Irritancy (score) Between P-value: C + B < B.	Mid (10)	Measure: 0		Measure: 1		**NS**
		Papules (count) Count location: Unspecified. Baseline counts: 19 (Target) / 16 (Comparator)	Mid (10)	Percent Change*: -63		Percent Change*: -59		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
329 Parallel	N=79 Mod	**Pustules (count)** Count location: Unspecified. Baseline counts: 10 (Target) / 8 (Comparator)	Mid (10)	Percent Change*: -79		Percent Change*: -72		
		Severity change (michaelsson %) Count location: Unspecified.	Mid (10)	Measure: -65		Measure: -59		**0.05**
	C.03.01			**Erythromycin**		**Vehicle**		
274 ↑ Parallel	N=187 Mild/mod	**Closed comedones (count)** Baseline counts: 8 (Target) / 3 (Comparator)	Short (4)	Percent Change*: -121		Percent Change*: -133		**NS**
89 Parallel	N=253 Mod/sev	**Closed comedones change (%)** Count location: Face.	Short (4)	Percent change: -10		Percent change: -20		**NS**
205 ↑ Parallel	N=225 Mild/mod	**Inflammatory (count)** Baseline counts: 25 (Target) / 24 (Comparator)	Short (4)	Percent Change*: -21		Percent Change*: -09		**0.004**
274	N=187	**Open comedones (count)** Baseline counts: 17 (Target) / 15 (Comparator)	Short (4)	Percent Change*: -133		Percent Change*: -127		**NS**
89 Parallel	N=253 Mod/sev	**Open comedones change (%)** Count location: Face.	Short (4)	Percent change: -22		Percent change: -18		**NS**
274 ↑ Parallel	N=187 Mild/mod	**Papules (count)** Baseline counts: 16 (Target) / 16 (Comparator)	Short (4)	Percent Change*: -129		Percent Change*: -113		**0.05**
89 Parallel	N=253 Mod/sev	**Papules change (%)** Count location: Face.	Short (4)	Percent change: -45		Percent change: -23		**NS**
285	N=26	**Papules change (%)** Count location: Face unspecified.	Short (4)	Percent change: -55		Percent change: -27		**0.01**
274 ↑ Parallel	N=187 Mild/mod	**Pustules (count)** Baseline counts: 4 (Target) / 4 (Comparator)	Short (4)	Percent Change*: -137		Percent Change*: -142		**NS**
89 Parallel	N=253 Mod/sev	**Pustules change (%)** Count location: Face.	Short (4)	Percent change: -52		Percent change: -24		**NS**
285	N=26	**Pustules change (%)** Count location: Face unspecified.	Short (4)	Percent change: -11		Percent change: -67		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
205 ↑ Parallel	N=225 Mild/mod	**Severity (cook)**	Short (4)	Measure: 3 (1.)		Measure: 4 (1.)		**0.003**
89 Parallel	N=253 Mod/sev	**Total lesions change (%)** Count location: Face.	Short (4)	Percent change: -30		Percent change: -20		**NS**
184 ↑ Parallel	N=175 Mod	**Inflammatory (group count)** Count location: Entire (with estimate).	Short (6)	Percent Change*: -99		Percent Change*: -99		**0.029**
157 Parallel Mod/sev	N=29 split face	**Severity change (plewig)**	Short (6)	Measure: -2 (0.7)		Measure: -1 (0.6)		**NS***
274 ↑ Parallel	N=187 Mild/mod	**Closed comedones (count)** Baseline counts: 8 (Target) / 3 (Comparator)	Mid (8)	Percent Change*: -122		Percent Change*: -185		**NS**
		Open comedones (count) Baseline counts: 17 (Target) / 15 (Comparator)	Mid (8)	Percent Change*: -144		Percent Change*: -131		**0.01**
		Papules (count) Baseline counts: 16 (Target) / 16 (Comparator)	Mid (8)	Percent Change*: -139		Percent Change*: -126		**0.05**
		Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Mid (8)	Percent Change*: -149		Percent Change*: -132		**0.05**
89 Parallel	N=253 Mod/sev	**Closed comedones change (%)** Count location: Face.	Mid (12)	Percent change: -25		Percent change: -20		**NS**
205 ↑ Parallel	N=225 Mild/mod	**Inflammatory (count)** Baseline counts: 25 (Target) / 24 (Comparator)	Mid (12)	Percent Change*: -46		Percent Change*: -19		**0.001**
184 Parallel	N=175 Mod	**Inflammatory (group count)** Count location: Entire (with estimate).	Mid (12)	Percent Change*: -99		Percent Change*: -99		**0.001**
89 Parallel	N=253 Mod/sev	**Open comedones change (%)** Count location: Face.	Mid (12)	Percent change: -30		Percent change: -20		**NS**
285	N=26	**Papules change (%)** Count location: Face unspecified.	Mid (12)	Percent change: -71		Percent change: -43		**0.01**
89	N=253	**Papules change (%)** Count location: Face.	Mid (12)	Percent change: -55		Percent change: -45		**0.025**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
285 Parallel	N=26 Mod/sev	**Pustules change (%)** Count location: Face unspecified.	Mid (12)	Percent change: -78		Percent change: -53		
89	N=253	**Pustules change (%)** Count location: Face.	Mid (12)	Percent change: -64		Percent change: -50		**NS**
205 ↑ Parallel	N=225 Mild/mod	**Severity change (cook %)**	Mid (12)	Measure: -40 (33.)		Measure: -22 (36.)		**NS***
89 Parallel	N=253 Mod/sev	**Total lesions change (%)** Count location: Face.	Mid (12)	Percent change: -40		Percent change: -30		**0.01**
	C.03.01			**Erythromycin (topical)**		**Placebo**		
39 Parallel	N=94 Mild/mod/sev	**Inflammatory (counts)** Count location: Unspecified. Between P-value: E<BP.	Short (4)	Measure: 12 (9.)		Measure: 19 (14.)		**0.01**
		Non-inflammatory (count) Count location: Unspecified. Between P-value: E<BP.Baseline counts: 33 (Target) / 32 (Comparator)	Short (4)	Percent Change*: -08		Percent Change*: -05		**NS***
		Severity (Leeds) Count location: Unspecified.	Short (4)	Measure: 1 (0.33)		Measure: 1 (0.38)		**0.01**
		Total Lesions (count) Count location: Unspecified. Between P-value: E>P.Baseline counts: 61 (Target) / 59 (Comparator)	Short (4)	Percent Change*: -16		Percent Change*: 02		**0.01**
		Inflammatory (count) Count location: Unspecified. Between P-value: E>P.Baseline counts: 20 (Target) / 20 (Comparator)	Mid (8)	Percent Change*: -34		Percent Change*: -17		**0.01**
		Non-inflammatory (count) Count location: Unspecified. Between P-value: E<BP.Baseline counts: 33 (Target) / 32 (Comparator)	Mid (8)	Percent Change*: -10		Percent Change*: -02		**NS***
		Severity (Leeds) Count location: Unspecified.	Mid (8)	Measure: 1 (0.27)		Measure: 1 (0.32)		**0.001**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
39 Parallel	N=94 Mild/mod/sev	**Total Lesions (count)** Count location: Unspecified. Between P-value: E>P.Baseline counts: 61 (Target) / 59 (Comparator)	Mid (8)	Percent Change*: -20		Percent Change*: 00		**0.01**
	C.03.025			**Erythromycin (topical)**		**Benzoyl Peroxide**		
39 Parallel	N=94 Mild/mod/sev	**Inflammatory (counts)** Count location: Unspecified. Between P-value: E<BP.	Short (4)	Measure: 12 (9.)		Measure: 13 (9.)		**0.01**
		Non-inflammatory (count) Count location: Unspecified. Between P-value: E<BP.Baseline counts: 33 (Target) / 33 (Comparator)	Short (4)	Percent Change*: -08		Percent Change*: -24		**NS***
		Severity (Leeds) Count location: Unspecified.	Short (4)	Measure: 1 (0.33)		Measure: 1 (0.27)		**0.01**
		Total Lesions (count) Count location: Unspecified. Between P-value: E>P.Baseline counts: 61 (Target) / 63 (Comparator)	Short (4)	Percent Change*: -16		Percent Change*: -24		**0.01**
		Inflammatory (count) Count location: Unspecified. Between P-value: E>P.Baseline counts: 20 (Target) / 20 (Comparator)	Mid (8)	Percent Change*: -34		Percent Change*: -39		**0.01**
		Non-inflammatory (count) Count location: Unspecified. Between P-value: E<BP.Baseline counts: 33 (Target) / 33 (Comparator)	Mid (8)	Percent Change*: -10		Percent Change*: -29		**NS***
		Severity (Leeds) Count location: Unspecified.	Mid (8)	Measure: 1 (0.27)		Measure: 0 (0.33)		**0.001**
		Total Lesions (count) Count location: Unspecified. Between P-value: E>P.Baseline counts: 61 (Target) / 63 (Comparator)	Mid (8)	Percent Change*: -20		Percent Change*: -31		**0.01**
	C.04.01			**Fusiden**		**Vehicle**		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
151 Parallel	N=79 Mild/mod	**Comedones (count)** Count location: 5 cm diameter. Baseline counts: 7 (Target) / 8 (Comparator)	Short (6)	Percent Change*: -16		Percent Change*: -31		**NS**
		Inflammatory (count) Count location: 5 cm diameter. Baseline counts: 11 (Target) / 10 (Comparator)	Short (6)	Percent Change*: -62		Percent Change*: -36		**0.001**
	C.04.01			**Fusidic acid**		**Placebo**		
315 Parallel	N=56	**Inflammatory change (%)**	Short (4)	Percent change: -13 (18.)		Percent change: -20 (12.)		**NS**
		Non-inflammatory change (%)	Short (4)	Percent change: 0 (20.)		Percent change: 17 (20.)		**NS**
		Severity change (leeds)	Short (4)	Measure: -20 (12.)		Measure: -25 (10.)		**NS**
		Inflammatory change (%)	Mid (12)	Percent change: -19 (25.)		Percent change: -28 (18.)		**NS**
		Non-inflammatory change (%)	Mid (12)	Percent change: -12 (20.)		Percent change: 17 (30.)		**NS**
		Severity change (leeds)	Mid (12)	Measure: -37 (15.)		Measure: -30 (15.)		**NS**
	C.05.005			**Meclocycline**		**Vehicle**		
194 Parallel	N=134 Mod/sev	**Inflammatory change (median %)** Count location: Face.	Short (5)	Measure: -49		Measure: -26		**0.001**
		Comedones (count) Count location: Face. Baseline counts: 88 (Target) / 90 (Comparator)	Mid (11)	Percent Change*: -32		Percent Change*: -100		
		Inflammatory change (median %) Count location: Face.	Mid (11)	Measure: -57		Measure: -22		**0.001**
	C.05.01			**Meclocycline**		**Benzoyl peroxide**		
30 ↑ Parallel	N=102 Mod	**Comedones (count)** Count location: Face. Baseline counts: 12 (Target) / 10 (Comparator)	Short (6)	Percent Change*: -26		Percent Change*: -58		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
30 ↑ N=102 Parallel Mod		**Papules (count)** Count location: Face. Baseline counts: 21 (Target) / 21 (Comparator)	Short (6)	Percent Change*: -24		Percent Change*: -48		
		Pustules (count) Count location: Face. Baseline counts: 9 (Target) / 9 (Comparator)	Short (6)	Percent Change*: -28		Percent Change*: -56		
		Comedones (count) Count location: Face. Baseline counts: 12 (Target) / 10 (Comparator)	Mid (10)	Percent Change*: -30		Percent Change*: -68		**0.01**
		Papules (count) Count location: Face. Baseline counts: 21 (Target) / 21 (Comparator)	Mid (10)	Percent Change*: -33		Percent Change*: -62		**NS**
		Pustules (count) Count location: Face. Baseline counts: 9 (Target) / 9 (Comparator)	Mid (10)	Percent Change*: -34		Percent Change*: -58		**NS**
	C.06.01			**Metronidazole**		**Placebo**		
328 ↑ N=96 Parallel Mild/mod		**Inflammatory (count)** Baseline counts: 24 (Target) / 23 (Comparator)	Short (4)	Percent Change*: -06	*NS*	Percent Change*: -03		**NS**
		Non-inflammatory (count) Baseline counts: 6 (Target) / 8 (Comparator)	Short (4)	Percent Change*: 146	*NS*	Percent Change*: 03	*NS*	**NS**
		Inflammatory (count) Baseline counts: 24 (Target) / 23 (Comparator)	Mid (12)	Percent Change*: -32	*NS*	Percent Change*: -25	*NS*	**NS**
		Non-inflammatory (count) Baseline counts: 6 (Target) / 8 (Comparator)	Mid (12)	Percent Change*: -18	*NS*	Percent Change*: -36	*NS*	**NS**
	C.08.01			**Tetracycline (topical) + placebo (oral)**		**Vehicle (topical) + placebo (oral)**		
10 N=60 Parallel Mod		**Severity (anderson)** Count location: Butterfly.	Short (6)	Measure: 3	*NS*	Measure: 4	*NS*	**NS**
	C.08.01			**Tetracycline hydrochloride (topical) + placebo (or**		**Placebo (topical) + placebo (oral)**		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
23 ↑ N=75 Parallel Mod		**Severity change (cook)** Count location: Entire face-(photos).	Short (6)	Measure: -1 (0.85)		Measure: 0 (1.)		**0.05**
		Severity change (cook))	Long (13	Measure: -1 (1.4)		Measure: -1 (1.2)		**0.05**
	C.08.01			**Tetracycline hydrochloride (topical) + placebo**		**Placebo + placebo**		
313 ↑ N=149 Parallel Mild/mod		**Severity (cook)** Count location: Face. Between P-value: with respect to oral.	Short (4)	Measure: 3	*.05*	Measure: 4	*NS*	**NS**
		Severity (cook) Count location: Face. Between P-value: with respect to oral.	Mid (12)	Measure: 2	*.05*	Measure: 3	*NS*	**NS**
	C.08.03			**Tetracycline (topical) + placebo (oral)**		**Benzoyl peroxide + placebo (oral)**		
255 N=69 Parallel Mod		**Back severity (leeds)** Count location: Back.	Mid (12)	Measure: 0 (0.47)	*NS*	Measure: 0 (0.41)	*NS*	**NS**
		Chest severity (leeds) Count location: Chest.	Mid (12)	Measure: 0 (0.26)	*NS*	Measure: 0 (0.4)	*NS*	**NS**
		Face severity (leeds) Count location: Face.	Mid (12)	Measure: 0	*.01*	Measure: 1	*.001*	**NS**
		Inflammatory (count) Baseline counts: 65 (Target) / 57 (Comparator)	Mid (12)	Percent Change*: -35	*.02*	Percent Change*: -42	*.001*	**NS**
		Non-inflammatory (count)	Mid (12)	Raw count: 43	*.003*	Raw count: 31	*.001*	**NS**
	C.09.01			**Triclosan**		**Vehicle**		
114 ↓ N=72 Parallel Mild/mod		**Inflammatory (adjusted count)** Count location: Entire face.	Short (4)	Raw count: 14 (11.)		Raw count: 16 (11.)		**NS**
		Inflammatory (score)	Short (4)	Measure: 2		Measure: 2		**NS**
		Non-inflammatory (count)	Short (4)	Raw count: 37 (11.)		Raw count: 43 (11.)	*NS*	**0.05**
		Overall change/patient (vas)	Short (4)	Measure: 2		Measure: 1		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
114 ↓ N=72 Parallel Mild/mod		**Inflammatory (count)** Count location: Entire face. Between P-value: with respect to vehicle.	Mid (8)	Raw count: 11 (11.)		Raw count: 16 (11.)		**0.05**
		Inflammatory (score) Count location: Entire face.	Mid (8)	Measure: 1		Measure: 2		**NS**
		Non-inflammatory (count)	Mid (8)	Raw count: 34 (11.)	*.05*	Raw count: 41 (11.)	*NS*	**0.01**
		Overall change/patient (vas)	Mid (8)	Measure: 3		Measure: 2		
	C.09.03			**Triclosan + propylene phenoxetol**		**Vehicle**		
114 ↓ N=72 Parallel Mild/mod		**Inflammatory (adjusted count)** Count location: Entire face.	Short (4)	Raw count: 14 (9.)		Raw count: 16 (11.)		**NS**
		Inflammatory (score)	Short (4)	Measure: 2		Measure: 2		**NS**
		Non-inflammatory (count)	Short (4)	Raw count: 35 (9.)	*.01*	Raw count: 43 (11.)	*NS*	**NS***
		Overall change/patient (vas)	Short (4)	Measure: 2		Measure: 1		
		Inflammatory (count) Count location: Entire face. Between P-value: with respect to vehicle.	Mid (8)	Raw count: 12 (9.)		Raw count: 16 (11.)		**0.05**
		Inflammatory (score) Count location: Entire face.	Mid (8)	Measure: 1		Measure: 2		**NS**
		Non-inflammatory (count)	Mid (8)	Raw count: 34 (9.)	*.05*	Raw count: 41 (11.)	*NS*	**0.005**
		Overall change/patient (vas)	Mid (8)	Measure: 3		Measure: 2		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.